Publication:
Characteristics and Outcomes of Patients With Systemic Sclerosis (Scleroderma) Requiring Renal Replacement Therapy in Europe: Results From the ERA-EDTA Registry.

dc.contributor.authorHruskova, Zdenka
dc.contributor.authorPippias, Maria
dc.contributor.authorStel, Vianda S
dc.contributor.authorAbad-Díez, Jose M
dc.contributor.authorBenítez Sánchez, Manuel
dc.contributor.authorCaskey, Fergus J
dc.contributor.authorCollart, Frederic
dc.contributor.authorDe Meester, Johan
dc.contributor.authorFinne, Patrik
dc.contributor.authorHeaf, James G
dc.contributor.authorMagaz, Angela
dc.contributor.authorPalsson, Runolfur
dc.contributor.authorReisæter, Anna Varberg
dc.contributor.authorSalama, Alan D
dc.contributor.authorSegelmark, Mårten
dc.contributor.authorTraynor, Jamie P
dc.contributor.authorMassy, Ziad A
dc.contributor.authorJager, Kitty J
dc.contributor.authorTesar, Vladimir
dc.date.accessioned2023-01-25T10:21:32Z
dc.date.available2023-01-25T10:21:32Z
dc.date.issued2018-08-16
dc.description.abstractData for outcomes of patients with end-stage renal disease (ESRD) secondary to systemic sclerosis (scleroderma) requiring renal replacement therapy (RRT) are limited. We examined the incidence and prevalence of ESRD due to scleroderma in Europe and the outcomes among these patients following initiation of RRT. Registry study of incidence and prevalence and a matched cohort study of clinical outcomes. Patients represented in any of 19 renal registries that provided data to the European Renal Association-European Dialysis and Transplant Association (ERA-EDTA) Registry between 2002 and 2013. Scleroderma as the identified cause of ESRD. Incidence and prevalence of ESRD from scleroderma. Recovery from RRT dependence, patient survival after ESRD, and graft survival after kidney transplantation. Incidence and prevalence were calculated using population data from the European Union and standardized to population characteristics in 2005. Patient and graft survival were compared with 2 age- and sex-matched control groups without scleroderma: (1) diabetes mellitus as the cause of ESRD and (2) conditions other than diabetes mellitus as the cause of ESRD. Survival analyses were performed using Kaplan-Meier analysis and Cox regression. 342 patients with scleroderma (0.14% of all incident RRT patients) were included. Between 2002 and 2013, the range of adjusted annual incidence and prevalence rates of RRT for ESRD due to scleroderma were 0.11 to 0.26 and 0.73 to 0.95 per million population, respectively. Recovery of independent kidney function was greatest in the scleroderma group (7.6% vs 0.7% in diabetes mellitus and 2.0% in other primary kidney diseases control group patients, both P No data for extrarenal manifestations, treatment, or recurrence. Survival of patients with scleroderma who receive dialysis for more than 90 days was worse than for those with other causes of ESRD. Patient survival after transplantation was similar to that observed among patients with ESRD due to other conditions. Patients with scleroderma had a higher rate of recovery from RRT dependence than controls.
dc.identifier.doi10.1053/j.ajkd.2018.05.016
dc.identifier.essn1523-6838
dc.identifier.pmid30122544
dc.identifier.unpaywallURLhttps://pure.uva.nl/ws/files/29428268/Front_matter.pdf
dc.identifier.urihttp://hdl.handle.net/10668/12852
dc.issue.number2
dc.journal.titleAmerican journal of kidney diseases : the official journal of the National Kidney Foundation
dc.journal.titleabbreviationAm J Kidney Dis
dc.language.isoen
dc.organizationHospital Universitario Juan Ramón Jiménez
dc.page.number184-193
dc.pubmedtypeJournal Article
dc.pubmedtypeMulticenter Study
dc.pubmedtypeResearch Support, Non-U.S. Gov't
dc.rights.accessRightsopen access
dc.subjectSystemic sclerosis
dc.subjectdialysis
dc.subjectdisease course
dc.subjectdisease registry
dc.subjectend-stage renal disease (ESRD)
dc.subjectincidence
dc.subjectkidney transplantation
dc.subjectmortality
dc.subjectoutcomes
dc.subjectprognosis
dc.subjectrenal recovery
dc.subjectrenal replacement therapy (RRT)
dc.subjectscleroderma
dc.subject.meshAdult
dc.subject.meshAged
dc.subject.meshCase-Control Studies
dc.subject.meshCause of Death
dc.subject.meshEurope
dc.subject.meshFemale
dc.subject.meshHumans
dc.subject.meshInternationality
dc.subject.meshKaplan-Meier Estimate
dc.subject.meshKidney Failure, Chronic
dc.subject.meshMale
dc.subject.meshMiddle Aged
dc.subject.meshPredictive Value of Tests
dc.subject.meshPrognosis
dc.subject.meshProportional Hazards Models
dc.subject.meshRegistries
dc.subject.meshRenal Replacement Therapy
dc.subject.meshRetrospective Studies
dc.subject.meshRisk Assessment
dc.subject.meshScleroderma, Systemic
dc.subject.meshSurvival Analysis
dc.subject.meshTreatment Outcome
dc.subject.meshYoung Adult
dc.titleCharacteristics and Outcomes of Patients With Systemic Sclerosis (Scleroderma) Requiring Renal Replacement Therapy in Europe: Results From the ERA-EDTA Registry.
dc.typeresearch article
dc.type.hasVersionVoR
dc.volume.number73
dspace.entity.typePublication

Files